The Investor
23 Feb 2026, 20:46
Gilead Sciences, Inc. announced a definitive agreement to acquire Arcellx, Inc. for $115 per share in cash plus a $5 contingent value right, representing an implied equity value of $7.8 billion.
The deal gives Gilead full control of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. The FDA has accepted the biologics license application, with a PDUFA action date of December 23, 2026. Gilead expects the transaction to accelerate development and commercialization while eliminating profit-sharing, milestone payments and royalties.
The transaction is anticipated to close in the second quarter of 2026, subject to regulatory approvals and tender conditions, and is expected to be accretive to earnings per share in 2028 and thereafter.
Source: Business Wire
The deal gives Gilead full control of anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for relapsed or refractory multiple myeloma. The FDA has accepted the biologics license application, with a PDUFA action date of December 23, 2026. Gilead expects the transaction to accelerate development and commercialization while eliminating profit-sharing, milestone payments and royalties.
The transaction is anticipated to close in the second quarter of 2026, subject to regulatory approvals and tender conditions, and is expected to be accretive to earnings per share in 2028 and thereafter.
Source: Business Wire